Why Cytek Biosciences, Inc.’s (CTKB) Stock Is Down 5.15%
As of Thursday, October 08, Cytek Biosciences, Inc.’s CTKB share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Cynthia McLaughlin
Cynthia McLaughlin
Rosalio Madrigal
Jenna Brashear
| Share Statistics | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $726.6 | $3,830.2 | 42% |
|
| Shares Out (Mil) | 129.5 | 105.4 | 68% |
|
| Institutional Ownership | 85.7% | 88.5% | 54% |
|
| Float (Mil) | 102.9 | 82.3 | 61% |
|
| Beta | 1.17 | 1.19 | 69% |
|
| Avg Daily Volume (000s) | 949 | 917 | 69% |
|
| Price Change (52-week) |
36.0% | 83.9% | 79% |
|
| Growth | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.8% | 7.5% | 76% |
|
| Net Income (5yr) | (40.3%) | (9.8%) | 9% |
|
| EPS (5yr) | (48.5%) | 2.8% | 4 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (14.9%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.070) | ($0.343) | ($0.253) | |
| Month Ago EPS | na | ($0.120) | $0.070 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.030 | ($0.030) | $0.200 | |
| Year/Year Chg | (25.5%) | (34.2%) | (58.7%) | |
| Financials | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $207 | $793 | 32% |
|
| Net Income (TTM) (Mil) | ($81) | ($31) | 13% |
|
| EPS (TTM) | ($0.627) | ($0.300) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | $39 | 24% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $6 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $274 | 30% |
|
| Enterprise Value (Q1) (Mil) | $390 | $3,688 | 32% |
|
| Valuation | CTKB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.25 | 3.62 | 58% |
|
| P/E | na | 44.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.6 | na |
|
| Ratios | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 51.9% | 48.1% | 64% |
|
| Net Margin | (39.0%) | (4.6%) | 13% |
|
| ROA | (17.1%) | (4.7%) | 21% |
|
| ROE | (23.0%) | (7.7%) | 22% |
|
| Liabilities to Assets | 28.0% | 41.1% | 20% |
|
| F-Score | 3 | 5 | na |
|
Passing Stock Screens
As of 10/23/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors